This company recently went public with an IPO on Wednesday, August 5th 2026. They issued 17,000,000 shares at $15.00 - $17.00 per share. We will continue to update data for ATTO as it becomes available. NASDAQ:ATTO Attovia Therapeutics (ATTO) Stock Price, News & Analysis $19.84 -0.33 (-1.64%) As of 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Attovia Therapeutics Stock (NASDAQ:ATTO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Attovia Therapeutics alerts:Sign Up Key Stats Today's Range$18.50▼$20.1750-Day Range N/A52-Week Range$18.50▼$22.79Volume376,596 shsAverage Volume342,565 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs. Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. Its pipeline is centered on potential treatments for conditions involving dysregulated immune responses, although many of its programs remain in development and are subject to clinical and regulatory evaluation. As a development-stage biotechnology company, Attovia’s activities primarily involve research, preclinical studies, clinical trials and the advancement of its proprietary therapeutic pipeline. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on developing innovative treatments for inflammatory diseases.AI Generated. May Contain Errors. Read More Receive ATTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Attovia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATTO Stock News HeadlinesAttovia Therapeutics (NASDAQ:ATTO) Major Shareholder Purchases $9,999,995.00 in StockAugust 9 at 4:09 AM | americanbankingnews.comRedmile Group, Llc Purchases 400,000 Shares of Attovia Therapeutics (NASDAQ:ATTO) StockAugust 9 at 4:09 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 10 at 1:00 AM | Profits Run (Ad)Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Buys 400,000 SharesAugust 8 at 6:36 AM | insidertrades.comLife Sciences Xi L.P. Frazier Acquires 588,235 Shares of Attovia Therapeutics (NASDAQ:ATTO) StockAugust 7 at 6:36 AM | insidertrades.comSee More Headlines ATTO Stock Analysis - Frequently Asked Questions How have ATTO shares performed this year? Attovia Therapeutics' stock was trading at $21.90 on August 5, 2026. Since then, ATTO shares have decreased by 9.4% and is now trading at $19.84. When did Attovia Therapeutics IPO? Attovia Therapeutics (ATTO) raised $272 million in an initial public offering on Wednesday, August 5th 2026. The company issued 17,000,000 shares at $15.00-$17.00 per share. When does Attovia Therapeutics' quiet period expire? Attovia Therapeutics's quiet period expires on Monday, September 14th. Attovia Therapeutics had issued 17,000,000 shares in its IPO on August 5th. The total size of the offering was $289,000,000 based on an initial share price of $17.00. During Attovia Therapeutics' quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. Who are Attovia Therapeutics' major shareholders? Top institutional investors of Attovia Therapeutics include BlackRock Inc.. Insiders that own company stock include Life Sciences Xi LP Frazier, Global Strategic Fund I Venbio and Redmile Group, Llc. View institutional ownership trends. How do I buy shares of Attovia Therapeutics? Shares of ATTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ATTO CIK2058707 Webwww.attovia.com Phone(510) 399-5001FaxN/AEmployees44Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ATTO) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBofA: Digital Dollar Coming 2025-2030If you've got $50k+ sitting in a bank account, you need to hear this. There's a plan to merge every dollar you...Decentralized Masters | SponsoredBernie is gunning for your moneyBernie Sanders introduced a bill proposing a one-time 50% tax on shares of America's most successful companies...Porter & Company | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...Awesomely | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Attovia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Attovia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.